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Aging comes with gradual loss of functions that increase the vulnerability to disease, senescence, and death. Themechanisms underlying
these processes are linked to a prolonged imbalance between damage and repair. Damaging mechanisms include oxidative stress,
mitochondrial dysfunction, chronodisruption, inflammation, and telomere attrition, as well as genetic and epigenetic alterations.
Several endogenous tissue repairing mechanisms also decrease. These alterations associated with aging affect the entire organism.
The most devastating manifestations involve the cardiovascular system and may lead to lethal cardiac arrhythmias. Together with
structural remodeling, electrophysiological and intercellular communication alterations during aging predispose to arrhythmic
events. Despite the knowledge on repairing mechanisms in the cardiovascular system, effective antiaging strategies able to reduce the
risk of arrhythmias are still missing. Melatonin is a promising therapeutic candidate due to its pleiotropic actions. This indoleamine
regulates chronobiology and endocrine physiology. Of relevance, melatonin is an antiaging, antioxidant, antiapoptotic,
antiarrhythmic, immunomodulatory, and antiproliferative molecule. This review focuses on the protective effects of melatonin on
age-induced cardiac functional and structural alterations, potentially becoming a new fountain of youth for the heart.
1. Introduction
Cardiovascular diseases are the first cause of death globally
[1, 2], with predominance in older populations. As many dif-
ferent mechanisms are involved in the relationship between
cardiovascular disease and aging, a wide range of study
models exploring different pathways have been developed
to understand these processes [3]. An important proportion
of deaths in patients suffering from cardiovascular diseases
is associated with abnormalities in the rhythm of the heart,
so-called cardiac arrhythmias. Not only in diseased patients
but also in healthy populations, age is a major risk factor
for arrhythmia development, causing substantial increases
in the levels of morbidity and mortality [4, 5]. Due to the
extensive structural and functional remodeling of cardiac
tissue in the elderly, arrhythmias can relatively frequently
occur in individuals who never developed any cardiac condi-
tion before. Thus, there is an intensive effort to understand
the mechanisms underlying age-induced arrhythmias, from
the molecular to the whole-organ level, as well as a great
interest in creating new strategies for their prevention that
might also ameliorate cardiac function in the elderly.
Despite differences between individuals and species due to
molecular mechanisms involving genetic and environmental
variability, damage caused by oxidative stress is considered
one of the main elements underlying the aging process [6, 7].
Mitochondria have been shown as one of the most important
regulators of aging [8]. Reactive oxidative species (ROS),
among other oxidative molecules, have been associated with
damaged and aged myocardium, playing an important role in
cardiac physiology and pathophysiology, as in the case of atrial
fibrillation (AF), the most commonly diagnosed cardiac
arrhythmia with particularly high prevalence in the elderly [9].
Different drugs have been studied and used in pharmaco-
therapy to improve the fight against aging and cardiac
arrhythmias [10–12]. Although these antiarrhythmic drugs
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must be used with caution in patients due to their potential
adverse effects, positive results of some of them have been
reported [13–15], including those of the molecule melatonin.
Thanks to its pleiotropic action, melatonin is still considered
one of the potentially good candidates for arrhythmia treat-
ment and prevention [16, 17]. Moreover, its antioxidant role
should be considered as an important factor to understand its
benefits in relation to aging [18–20].
In this review article, we present an overview of arrhyth-
mias and their molecular mechanisms in aged hearts.
Considering the pleiotropic effects of melatonin, we focus
our interest on the action of this molecule in cardiac tissue.
We highlight its potential as a drug against oxidative stress
and for antiarrhythmic treatment in aged hearts, which could
make melatonin a prospective candidate to become the foun-
tain of youth for the heart.
2. Aging: Body and Heart Rhythms
2.1. Aging of the Heart. Aging is a complex process. As many
human functions decline with age, the incidence and preva-
lence of diseases increase. Nevertheless, the apparent cycle of
life postpones its ending due to human interventions. Improve-
ments in access to shelter, water, and food have doubled life
expectancy at birth in the past century. Despite disparities in
social support or medical care underlying uneven life expec-
tancy across countries, the proportion of older individuals
keeps on increasing globally. This aging of the population
comes associated with growing costs related to health care to
the elderly all over the world [21].
The relationship between aging and age-related disease
remains controversial [21–23]. Some postulate that such a
distinction between pathological and nonpathological aging
does not invalidate the fundamental underlying molecular
mechanisms, which would be potentially shared in the two
cases. On the other hand, others support a clear difference
between aging and diseases, claiming that aging is not a
disease itself but leads to higher vulnerability, implying that
different molecular pathways would be involved in each case.
For the purpose of this review, we accept that the basic mech-
anism of aging is the prolonged imbalance between damage
and repair [24–26].
Overall, there are three great classes of mechanisms
underlying the aging of the organism: (1) inadequate repair
of damage, (2) cell number deregulation, and (3) damage
caused by oxidative stress [27, 28]. The factors underlying
the damage-repair imbalance vary between species and
between different individuals of the same species due to the
effect of genetic processes and environmental variability.
Specifically in the cardiovascular system, a major prob-
lem in aged hearts is the generation of cardiac arrhythmias
[29]. Although arrhythmias are most frequently related to
heart diseases, they can also occur in nondiseased hearts,
with the probability of occurrence exponentially increasing
with age. Arrhythmias originating both in the atria and in
the ventricles, such as AF, atrial flutter, premature ventricular
contractions, ventricular tachycardias, or ventricular fibrilla-
tion [30], have an increased prevalence in elderly individuals.
Changes in cardiac structure and function that accompany
aging and possibly predispose the aged hearts to increased
arrhythmic risk have been reported mainly in animal models
due to the difficulties in assessing the effects of aging inde-
pendently of disease in human hearts.
2.2. Structural, Electrical, and Autonomic Changes in
Aged Hearts
2.2.1. Structural and Autonomic Changes.The heart undergoes
age-induced structural changes. Different studies have docu-
mented atrial remodeling associated with larger atrial size
and volume [31]. In the ventricle, structural remodeling has
been associated with left ventricular hypertrophy related to
increased wall thickness [32]. Also, there is a loss of cardio-
myocytes in the heart by necrotic and apoptotic cell death with
age [33]. Cellular mechanisms of senescence are yet to be fully
understood in aging. There is evidence about the link between
AF and the presence of senescence markers, one of them being
p16 (p16INK4a, cyclin-dependent kinase inhibitor 2A), which is
involved in inflammation. Importantly, aging is characterized
by notably increased fibrosis due to a rise in the number of car-
diac fibroblasts [34, 35], which are the cells primarily responsi-
ble for the production of extracellular matrix components like
collagen [36] and proteoglycans [37]. These changes are
accompanied by alterations in the cell-to-cell coupling between
neighbouring myocytes, which are mediated by changes in gap
junction distribution and connexin expression [38].
Aging is additionally associated with changes in the
autonomic nervous system (ANS), which regulates the activity
of internal body organs like the heart, as well as in the cardiac
response to autonomic stimuli [39, 40]. Regarding the
sympathetic branch of the ANS, reduced responsiveness to
sympathetic nerve stimulation of both aged atria and aged
ventricles has been evidenced, although some studies have pos-
tulated that this occurs through different mechanisms.Whereas
in the aged atria the involved mechanism may be related to
decreased β-adrenergic responsiveness, in the aged ventricles
it may be related to nerve degeneration [41, 42]. Other studies
have described that age alters cardiac adrenergic responsive-
ness, being the age-induced changes related to a reduction in
the density of β-adrenoceptors and reduced cAMP in associa-
tion with abnormalities in G protein and kinase activity.
Although these changes vary between tissues and between
species [43], the ability of the heart to properly respond to auto-
nomic stimuli has been generally documented to decrease with
aging [44]. Reduced β-adrenoceptor responses and receptor
densities have been identified in the aging myocardium [43,
45, 46], exacerbated by decreased cAMP production. It is not
fully clear how impaired cAMP-dependent regulation of the
slow delayed rectifier potassium current (IKs) [47] and L-type
calcium current (ICa-L) [48] translates into alterations of
repolarization reserve in the elderly. On the other hand, less
research has been dedicated to the investigation of aging effects
on the cardiac response to parasympathetic stimuli [49, 50].
Nevertheless, available studies suggest a reduction in parasym-
pathetic regulation with age accompanied by blunted respon-
siveness of the heart to parasympathetic withdrawal [51].
The density and function of atrial muscarinic type 2 receptors
are thought to decline with age [42]. Furthermore, some
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studies have specifically reported on how age alters the
response of cardiac tissue to the interaction between sympa-
thetic and parasympathetic stimuli, showing that the action
of β-adrenergic stimulation to antagonize cholinergic effects
declines in old atria, which could increase arrhythmia suscep-
tibility [52].
The aged-induced structural remodeling and the
impaired response to autonomic stimulation in aged hearts,
together with the electrical remodeling described in Section
2.2.2, all contribute to reduced cardiac adaptive responses
and increased risk for arrhythmias.
2.2.2. Electrophysiological Changes. Cardiac contraction is
triggered by a bioelectrical signal, known as action potential
(AP). The AP is the result of the electrical potential difference
between the intra- and extracellular spaces and involves the
opening and closing of complex transmembrane proteins
known as ion channels, among other molecules. Both AP
generation and propagation are key to ensure proper heart
electrical function leading to optimal cardiac output [53, 54].
Aging is associated with remarkable electrical alterations
leading to remodeling of both atrial and ventricular tissues
[55, 56]. In atrial myocardium, contradictory results on the
effects of age on ionic currents have been described, with some
studies indicating relevant changes in sodium currents and
other studies showing no significant alterations in these
currents with age [57, 58]. Increased potassium and decreased
calcium currents with age have been observed in atrial myo-
cytes from older animals too. In the ventricular myocardium,
decreased potassium currents as well as delayed inactivation
and/or increasedmagnitude of calcium currents, accompanied
by adjustments in calcium cycling, have been shown to con-
tribute to prolonged AP with age [59, 60].
In addition to the remodeling leading to delayed and
impaired cardiac impulse conduction due to a decrease in Con-
nexin 43 (Cx43) expression with aging [5, 61, 62], there are also
electrophysiological alterations in the sinoatrial node involving
depression of its activity, which could enhance initiation of the
electrical impulse in other cells of the heart [63]. Animal studies
suggest that decreased expression of potassium/sodium
hyperpolarization-activated cyclic nucleotide-gated channel 2,
ICa-L current, T-type calcium current, and voltage-gated
potassium (Kv) channels (Kv1.5 channels) can also play a role
[64–66].
Thus, age-associated ion channel remodeling in differ-
ent cardiac regions involves alterations in several families
of ion channels, with an impact on the AP [67, 68]. Those
channels could be potential targets to help to maintain
cardiac function in aged hearts [56].
2.3. Mechanisms Underlying Arrhythmias in Aged Hearts.
Although evidence suggests that cardiac aging is associated
with enhanced predisposition to arrhythmia development,
improved knowledge of the mechanisms underlying the
enhanced incidence of arrhythmias with aging is still needed.
New pharmacological approaches that selectively target the
molecular pathways involved in age-induced alterations
increasing arrhythmic risk might help prevent cardiovascular
diseases and retard the age-related decline in physiological
processes.
Age-induced changes in major ionic currents leading to
AP disturbances, together with other elements of structural,
electrical, and autonomic remodeling in the heart, can
increase arrhythmic risk [69, 70]. In particular, an increase
in the activity of the sodium-calcium exchanger (NCX)
may induce calcium overload, which can trigger arrhythmias
[71]. Increased expression of NCX and delayed inactivation
of ICa-L, together with reduced expression of SERCA and
other proteins related to calcium handling, all contribute to
impaired calcium homeostasis and provide mechanisms for
increased triggered activity in the aged myocardium [72–
76]. In addition, fibrosis accumulation and changes in gap
junction distribution and connexin expression with aging
lead to slower conduction in cardiac tissue, which increases
arrhythmia predisposition [77–82].
Dysfunction or senescence of cardiomyocytes has been
observed in aged hearts, with senescent cardiomyocytes exhi-
biting DNA damage response, endoplasmic reticulum stress,
mitochondria dysfunction, contractile dysfunction, hyper-
trophic growth, and senescence-associated secretory pheno-
type [83]. Cellular senescence contributes to the loss of
function and regenerative capacity of cardiac tissue and,
although the environment of an individual determines the
degree to which it can be a major causal factor for the
organism’s functional decline with aging, these changes and
damage in the genome can induce inflammation and pro-
mote the adverse remodeling described above [84, 85].
Oxidative stress is one of the main damaging processes
underlying aging. Indeed, increased production of ROS has
been shown to underlie some of the already described
elements of age-induced cardiac remodeling (Figure 1). The
signaling pathway driven by ROS regulates cardiac develop-
ment and maturation as well as calcium handling, excitation-
contraction coupling, and vascular tone [86, 87]. Excessive
ROS production can increase the threshold to trigger cardiopro-
tection and, in relation to the described structural, autonomic,
and electrical remodeling, could help explain the increased inci-
dence of damage and the consequent increase in arrhythmia
predisposition with aging [5], as further described in Section 3.
3. Oxidative Mechanism of Arrhythmias and
Antioxidant Antiarrhythmic Therapies
The exposure to different types of damage over time is highly
individual specific, partly explaining differences in the aging
rate between individuals [88, 89]. Of the many factors contrib-
uting to aging of the body, and in particular of the heart,
including genetics, epigenetics, diet, smoking, physical activity,
and even chance [90–92], here, we will focus on the relation-
ship between oxidative stress and age-induced arrhythmias
and we will revise antioxidant therapies that could provide
antiarrhythmic benefits.
3.1. Oxidative Stress in the Aging Heart and Relation to
Arrhythmic Risk. Although the mechanisms responsible for
senescence and remodeling in cardiomyocytes and aged
hearts are not fully understood, mitochondria have emerged
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as central regulators of the aging process [8, 86]. In the aged
myocardium, mitochondrial function is impaired at various
levels including ROS formation, dynamics, and metabolism.
Together with ROS, which is considered to be one of the
primary determinants of aging [93–95], the superoxide
anion, the hydroxyl radical, and hydrogen peroxide are in
fact crucial molecules with important roles in cardiac physi-
ology and pathophysiology through various signaling path-
ways [96].
Oxidative stress can work as a mediator of AF, with
elevated levels of ROS having been linked to it [97, 98], both
oxidative stress and AF being common in aged hearts. Also,
prooxidant genes are overexpressed and many antioxidant
genes are downregulated in AF. In addition, derivatives of
reactive oxidative metabolites and ratios of oxidized to
reduced glutathione and cysteine show high levels in blood
from patients suffering AF [99]. ROS facilitates ventricular
arrhythmia too, especially in aged and hypertensive rat
hearts, with underlying mechanisms involving the generation
of early afterdepolarizations [100].
Among the various possible ways for ROS to facilitate
arrhythmia development, alterations in ionic currents have
been revealed as an important factor [7, 101–103]. Ionic alter-
ations due to elevated ROS have been observed in the sodium-
potassium ATPase (Na/K-ATPase) pump, NCX, and K+ and
Na+ channels [104, 105]. In addition, the molecular mecha-
nism of arrhythmias induced by ROS could be linked to hydro-
gen peroxide (H2O2), a major contributor to oxidative stress,
producing complex cardiac effects that may involve altered
calcium homeostasis [106]. Moreover, there is evidence about
how ROS may act on the ICa-L current producing a leak of
Ca2+ from the sarcoplasmic reticulum (SR). Besides, ROS
decreases peak sodium current and SERCA-mediated SR
Ca2+ uptake. ROS participates in the inhibition of KATP chan-
nels [107] and decrease of the transient outward potassium
current (Ito) [108], among others [109]. All these mechanisms
are related to an increase in intracellular Ca2+ levels, AP pro-
longation, reduction in conduction velocity, and facilitation of
triggered activity and reentry. Also, dysregulation of L-type
calcium channels and an increase in late Na+ current may
result in arrhythmia [110–112]. The decrease in total Na+
current induced by elevated ROS may cause a reduction in
conduction velocity and provide a substrate for reentry [113].
On top of oxidative stress causing alterations in ion chan-
nels, its potential contribution to cardiac arrhythmias by
impairing intercellular communication has been additionally
described, both in relation to aging and to various patholog-
ical states. This effect may result in changes in conduction
properties. Specifically, elevated ROS levels decrease the
expression and distribution of Cx43, the main component
of gap junction channels in the ventricles and one of the most
important connexins in the atria [7, 114, 115]. This impairs
conduction through gap junctions and may facilitate cardiac
arrhythmias [116, 117]. Also, the effect of ROS radicals on car-
diac structure by promoting high levels of fibrosis may impede
the normal propagation of the AP across the heart. This effect
is due to proliferation of cardiac fibroblasts by the high level of
transforming growth factor beta 1 (TGF-β1) production
induced by increased ROS [118].
On the basis of the described mechanisms underpinning
oxidative stress as a key contributor to arrhythmias, further
studies delving into these different routes could help to iden-
tify molecules that can serve as therapeutic targets for oxida-
tive stress in the aged heart with antiarrhythmic benefits.
3.2. Markers of Oxidative Stress: Role on Antiarrhythmic
Therapies. Increased serum markers of oxidative stress might
be an important guide in selecting the individuals who will
most likely respond to antioxidant therapy and could benefit
from its possible antiarrhythmic effects [99, 119]. Studies
exploring novel molecular mechanisms for ROS-induced
arrhythmia have led to the discovery of new potential antiar-
rhythmic targets.
Among the mentioned potential mechanisms to be con-
sidered as targets against arrhythmias via oxidative stress
therapies, one of them is the abnormal splicing of cardiac
sodium channel mRNA in heart failure. This is a possible
mechanism underlying decreased sodium current in ranges
associated with sudden cardiac death, suggesting that inter-



















Figure 1: Schematic representation of different mechanisms, including increased production of reactive oxygen species, involved in
age-induced remodeling of the heart, from cell to organ level.
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arrhythmic risk [113, 120]. Moreover, Ca2+/calmodulin-
dependent kinase II (CaMKII) can be activated by ROS and
its activation likely mediates several of the reported ROS-
induced arrhythmogenic effects [121–123]. Several studies
have recently described the link between the use of CaMKII
inhibitors and the improvement in catecholaminergic poly-
morphic ventricular tachycardia, helping to inhibit arrhyth-
mic phenotypes [124]. As an additional mechanism that
could represent a potential source of new antiarrhythmic tar-
gets, it is worth mentioning the impact of oxidative stress on
the increased activity of ryanodine receptors (RyRs). Protein
kinase A hyperphosphorylates cardiac RyRs, which results in
a dysregulation of SR Ca2+, provoking a leak of calcium in
failing hearts that can trigger fatal ventricular arrhythmias
[10, 125–132].
However, the role of ROS scavengers is hampered by the
ability of ROS radicals to react with other molecules. A general
scavenger can usually neutralize one or a few forms of ROS,
but other forms of ROS remain to exert their proarrhythmic
effects. Clinical trials using general antioxidants have not
shown the expected therapeutic outcome. A more effective
antioxidant therapeutic approach targeting the sources of
ROS could be more beneficial. Among cardiac sources of
ROS, mitochondria and NADPH oxidase seem to be promis-
ing therapeutic targets for the management of AF, a common
arrhythmia in old age [133, 134]. Because mitochondria play a
central role in ROS-induced ROS release, mitochondria-
targeted antioxidant therapy may prove to be the most effec-
tive antioxidant therapy for the management of chronic AF
[86, 135–137].
The free radical theory of aging attributes aging processes
to the accumulation of damage inflicted by free radical species.
Among the different species involved in aging, we should
mention some antioxidants such as superoxide dismutase,
catalase, and metallothionein [138]. In Section 4, we will focus
our attention on the role of melatonin as a potential antioxi-
dant molecule against aging.
4. Melatonin as a Potential Antiarrhythmic
Treatment in Aging
4.1. Melatonin and Cardiac Activity. Even if further studies in
humans are needed, melatonin appears as a key molecule in
heart aging. Melatonin is an amphipathic and pleiotropic mol-
ecule, being able to act on several targets at different levels and
cell locations [139, 140]. Melatonin was first discovered in the
1950s by Lerner et al. [141], and it is considered the molecule
of the night, due to its increased levels during nighttime in the
majority of animal species. Melatonin ismainly secreted by the
pineal gland [142], and its production is considered to follow a
rhythmical pattern, making it a molecule involved in biologi-
cal seasonal and yearly rhythms of the organisms [143].
Melatonin has a double role in the sleep-wake cycle. This
molecule is able to entrain and shift the circadian rhythm
(chronobiotic function) and, in addition, plays its action on
the sleeping process, helping through a “hypnotic” function
by increasing the homeostatic drive to sleep [144]. At the
level of the pineal gland, production and release of melatonin
follow a clear circadian pattern, having its peak level of
synthesis during nighttime [145]. Melatonin has been
reported to have a cardioprotective role in various animal
species [146]. In fact, increases in melatonin during night-
time are linked to a good cardiovascular function in different
organisms. Reduced levels of melatonin are related to disease,
aging, and chronodisruption.
Melatonin has an apparent antioxidant function, slows
down aging, and expands the life expectancy, helping to delay
or avoid different age-related diseases [147, 148]. The molec-
ular mechanisms underlying those processes are still not fully
elucidated. The role of melatonin as a cardioprotective mole-
cule has been suggested as part of a pathway linked with its
antioxidative action in the heart [149]. However, other mech-
anisms related to ion channel interaction as well as positive
effects in mitochondria define its cardioprotective action
too. Melatonin acts via its receptors, which are expressed
throughout the body, including cardiac tissue [18]. The
pleiotropic action of this molecule in cardiac tissue makes
melatonin an interesting agent in preventive treatments,
particularly in relation to cardiac arrhythmias. Since the
work by Tan et al. in 1998 [150], our understanding of
melatonin as an antiarrhythmic molecule has increased
significantly, becoming an important and promising cardio-
protective molecule for the heart. Arrhythmia incidence has
been documented to decrease during nighttime hours, when
melatonin levels increase 30- to 70-fold. In particular, life-
threatening cardiac arrhythmias (ventricular tachycardia,
ventricular fibrillation, and sudden cardiac death) are more
likely to occur in the morning after waking up, when melato-
nin levels are lower or even undetectable.
In summary, melatonin presents different mechanisms of
action involving receptor activation, ion channel modulation,
improvement of mitochondrial functions, antioxidant effects,
and others. Based on these mechanisms and their implica-
tions to the aging process, melatonin is considered a key anti-
aging element through several pathways (Figure 2).
4.2. Melatonin Receptors. Melatonin receptors are character-
ized to have a wide range of locations. They can be found in
different regions within the cell, the plasma membrane being
a relevant location linked to the interaction with the melato-
nin molecule. Melatonin receptors can be found in several
systems and organs like the nervous system, kidneys, liver,
intestinal tract, prostate gland, uterus, skin, and eyes, as well
as the heart and the cardiovascular system [151]. These
receptors, named MT1 and MT2, and also known as Mel1a
and Mel1b, can play their role on melatonin action in the
organisms via cell membrane interaction and following a
pathway involving G proteins [152]. This melatonin interac-
tion with its receptors at the level of the plasma membrane
occurs with high affinity between the molecule of melatonin
(Kd ~ 0:1 pM) and each of MT1 and MT2 [153, 154].
Regarding the structure of the melatonin receptor, both
MT1 and MT2 can develop their role as monomers and
dimers. The MT1 homodimer forms in a proportion 3- to
4-fold higher than the MT2 homodimer and the MT1/MT2
heterodimer. In addition, there is anMT3 receptor, described
as a quinone reductase 2, with an affinity in the nanomolar
ranges [155]. Both MT1 and MT2 inhibit adenylate cyclase-
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protein kinase A-CREB signaling in target cells by pertussis
toxin-sensitive Gαi, β, and γ and toxin-insensitive Gq, β,
and γ proteins [151, 156]. The MT1 receptor also increases
phosphorylation of mitogen-activated protein kinase 1/2
(MAPK) and extracellular signal-regulated kinase 1/2
(ERK) and increases the potassium conductance through
inwardly rectifying (Kir3.x) channels. The effect on potas-
sium channels could be relevant to heart electrophysiology
since Kir3.x channels are highly expressed in cardiomyocytes
and are usually coupled to acetylcholine and adenosine
membrane receptors [157]. In the case of the MT2 melatonin
receptor, its activation inhibits both forskolin-stimulated
cAMP production and cGMP formation, activates protein
kinase C (PKC) in the nervous system, and decreases
calcium-dependent dopamine release in the retina. Native
functional MT1/MT2 heterodimers in mouse rod photore-
ceptors mediate melatonin’s enhancement of scotopic light
sensitivity through phospholipase C and PKC pathways
[158]. Different drugs such as Luzindole work as receptor
blockers, with an important role in cardiac tissue. Luzindole
and 4P-PDOT competitively block MT1 melatonin recep-
tors (in concentrations higher than 300nM), and both are
inverse agonists in systems with constitutively active MT1
receptors [148–155, 159].
Melatonin can act in the regulation of calcium levels due
to its interaction with intracellular proteins such as calmodu-
lin, calreticulin, or tubulin [160], all of these pathways being
potentially linked to the action of melatonin in the cardiovas-
cular system directly or indirectly [161]. In particular, the
role of the molecule of melatonin in mitochondrial pathways
has been described. Melatonin provides a potent protection
against mitochondrial-mediated lesions, playing an important
role in the organism in terms of energy production [162].
4.3. Antioxidant Effects of Melatonin.Deficiencies in the elec-
tron transport chain from mitochondria generates reactive
oxygen species and reactive nitrogen species (ROS/RNS)
[163–167]. Oxidative stress decreases respiratory complex
activity, impairs the electron transport system, and opens
the mitochondrial permeability transition pores leading to
cell death [165–169]. Melatonin has an antioxidant effect
through mitochondria, improving and preserving the good
function of complexes I and III and preventing the opening
of the mitochondrial permeability transition pores [170–
173]. In addition, melatonin prevents the high activity of
NADPH oxidase, which can be linked to the production of
oxidative species beyond mitochondria, considered as the
main source of oxidizing species during oxidative phosphor-
ylation [18, 164, 174].
The reduction of mitochondrial damage in the heart could
be related to the negative regulation of angiotensin II type 1
receptor (AT1) by melatonin [13]. In addition, sirtuin-1 and
sirtuin-3 are downstream mediators of the cardioprotective
actions of melatonin. Sirtuin-3 is a family member that is
primarily located in the mitochondria and protects against
inflammation and diseases related to oxidative stress. Melato-
nin elevates sirtuin-3, stimulates superoxide dismutase activ-
ity, and suppresses mitochondrial oxidative stress and, via
sirtuin-1 and sirtuin-3, it can also prevent isoproterenol-
induced mitochondrial injury [175].
Following the previously described pathways, melatonin
has been described to have an effect as a powerful antioxi-
dant, with a potency up to 10 times greater than vitamin E
[176], having an important role interacting against oxidative
species. Free radicals and nonradical reactive species have
been documented as one of the main molecules involved in





















Figure 2: Scheme about the effect of reactive oxygen species (ROS) in cardiac tissue at different levels. Also, the potential role of melatonin as
an antioxidant molecule and its implications for arrhythmia prevention are illustrated (CaMKII: Ca2+/calmodulin-dependent kinase II;
SERCA: sarco/endoplasmic reticulum Ca2+-ATPase; ROS: reactive oxygen species; ICa: calcium current; INa: sodium current; KATP:
ATP-sensitive potassium channel; NCX: sodium-calcium exchanger; ETC: electron transport chain; NOS: nitric oxide synthases; NADPH:
nicotinamide adenine dinucleotide phosphate hydrogen).
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them [163, 177]. Redox biology involves the study of ROS,
RNS, and reactive sulfur species as well as their role in the
damage of several molecules and tissues. Under physiological
conditions, ROS/RNS act as second intracellular messengers
modulating signal transduction pathways [164]. A good bal-
ance between the production and the removal of free radicals
is key to maintaining proper concentrations of this species in
the organism, thus avoiding damage. Melatonin may play a
crucial role in preserving such a good balance. However,
when oxidants increase above healthy levels, oxidative stress
occurs and represents a severe risk to the molecular integrity
of lipids, proteins, and DNA. Different molecules, including
melatonin, could work in the neutralization of reactive
species as scavenger molecules, generating a chemical way
of counteracting oxidative stress. In particular, the role and
interaction with mitochondria could be a good strategic
point, as this organelle is considered the main source of
oxidation. However, as mentioned before, there are many
other pathways to be detected, which create other oxidant
species, such as NADPH oxidase, which have their origin in
a different system beyond the mitochondrial one.
It is possible to classify different types of antioxidants as (1)
nonenzymatic ones (melatonin, vitamins, and GSH) and (2)
enzymatic ones (SOD, catalase, thioredoxin, and glutathione
peroxidase). It is worthy to mention that the melatonin mole-
cule is 5 times more effective than GSH, for instance [167,
178]. Melatonin stimulates antioxidant enzymes by acting on
membrane, cytoplasmic, and nuclear receptors [178, 179].
Lowmelatonin concentrations increase the expression or activ-
ity of SOD, catalase, and glutathione peroxidase [178, 180]. In
addition, melatonin can prevent oxidative stress. The aromatic
indole ring of melatonin reduces and repairs electrophilic
radicals acting as an electron donor. One molecule of melato-
nin can neutralize up to 10 toxic reagents, including ROS,
RNS, and other free radicals. Moreover, several metabolites
formed when melatonin neutralizes harmful reagents are also
antioxidants, suggesting that a cascade of reactions increases
the efficacy of melatonin. Being a highly lipophilic and hydro-
philic compound, melatonin crosses all morphological barriers
and acts not only in each cell but also within each subcellular
compartment. Additionally, melatonin increases the efficacy
of vitamin E, vitamin C, and GSH. Therefore, the elimination
of free radicals can be carried out by intracellular interactions
independent of any receptor [18].
Since free radicals are continuously produced from oxi-
dative reactions and melatonin production declines through
the human lifespan, exogenous melatonin could be used in
the aging population to improve health and reduce free
radical damage.
4.4. Cardioprotective Effects of Melatonin. The beneficial
effect of melatonin on health, disease, and aging has been
supported by many in vivo animal studies. In particular, the
potential of melatonin intake to improve cardiac function
and diminish oxidative stress has been demonstrated [181].
The antiarrhythmic effects of melatonin were first attributed
to its notable antioxidant properties. Melatonin has been
later suggested as a good candidate for cardiovascular dis-
eases and aging due to its role in modulating electrophysio-
logical properties from cell to tissue levels, its relation to
oxidative stress, and its important action in repairing and
controlling circadian rhythms [182]. Loss of the circadian
rhythm regulated by melatonin predisposes the heart to suffer
cardiac arrhythmias, particularly ventricular tachycardia, due
to conduction disorders and changes in repolarization [15].
Since melatonin levels decline progressively over a lifespan
[171, 183], loss of melatonin during aging could contribute
to a gradually increased predisposition to hypertension and
arrhythmias [18].
Melatonin has been shown to have a cardioprotective
role, including an antiarrhythmic effect, through different
pathways. Melatonin prevents renal damage and arrhythmo-
genic myocardial remodeling during unilateral ureteral
obstruction due to a decrease in oxidative stress, fibrosis,
and apoptosis associated with AT1 reduction and Hsp70-
VDR increase [13]. Other studies have reported a low level
in the synthesis of melatonin and low circulating levels of this
molecule in patients with coronary heart disease as well as in
patients with hypertension and heart failure [184–190].
Cardiac events, such as arrhythmias [191] and others [192],
more likely occur during the morning hours when levels of
melatonin are considered to be lower [193]. This evidence
supports the crucial role of endogenous melatonin in cardio-
vascular pathologies [194]. Melatonin can have an antiapop-
totic effect associated with restoring Nrf2 antioxidant
capacity (one of the main molecules responsible for detecting
oxidative stress damage), improving this way mitochondria
ultrastructure altered by aging [195]. Additionally, cardio-
protection by melatonin against oxidative stress and arrhyth-
mias could be widely explained by modulation of ion
channels, AP and Cx43 expression [196–198].
The action of melatonin in the opening of Kir3.x chan-
nels could explain its control of membrane potential [199].
In the nervous system, there is an effect of melatonin via
Kir.3x channels and linked to the circadian rhythm [200].
In fact, it is possible to see an effect on circadian sleep
regulation through suppression of GABAergic neurons by
melatonin in the lateral hypothalamus (a crucial function
for wakefulness) through Kir3.1/Kir3.2 channels and via the
MT1 receptor [199]. This interaction via the MT1 receptor
inactivates hyperpolarization-activated cyclic nucleotide-
gated channels [201]. Due to their important role in the
nervous system, Kir channels can also be involved in the
heart rate decrease mediated by the parasympathetic branch
of the autonomic nervous system [202].
Regarding sodium channels (Na+), oxidative stress can
increase the late sodium current through direct Na+ channel
modification, prolonging the AP and facilitating the genera-
tion of arrhythmogenic triggers known as early afterdepolar-
izations (EADs) [203–205]. In the case of calcium channels
(Ca2+), a redox regulation can occur in cardiac myocytes
via ryanodine receptors, IP3 receptor and ICa-L [105, 206].
Different species such as ROS and RNS affect the L-type
Ca2+ channel Cav1.2 through cysteine residues that can alter
the molecular levels of intracellular Ca2+ or modify specific
signaling molecules as in smooth muscle [207]. It has been
reported how a low-affinity interaction between melatonin
and calmodulin antagonizes the binding of Ca2+, involved
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in its antioxidant action and in electrophysiological signaling
[208–211]. In addition, melatonin acutely increases ICa-L in
chick cardiac membranes [212] and downregulates voltage-
sensitive calcium channels in the rat heart [213].
Voltage-gated potassium (Kv) channels contributing to
myocardial repolarization are sensitive to oxidative stress
[135, 214]. Particularly, the sulfenic acid, a conserved cyste-
ine residue of Kv1.5 channels, can induce arrhythmia under
prolonged oxidative stress [18, 214, 215]. The role of melato-
nin may depend on time and doses of administration, as it
happens via contact with certain channels such as Kv1.3 in
lymphocytes or other mechanisms in cardiomyocytes [216].
An example of a dose-dependent action of melatonin is the
interaction with KATP channels via mitochondria. The
preventive action of melatonin on the permeability transition
pore in this channel has been described as an important part
of its neuroprotective effect [217]. Its role against mitochon-
drial dysfunction has been described on myocardial tissue
too [170–173]. Nevertheless, the effect in the opening of
KATP channels in cardiac tissue at high concentrations of
melatonin could be proarrhythmic [218, 219].
On top of the important role of melatonin as a modulator
of ion channel properties, it has also a crucial and positive
effect in conduction in cardiac tissue due to its interaction
with Cx43, the most abundant connexin in the heart [220].
Connexin proteins assemble into intercellular channels at
gap junctions. The largest accumulation of connexins occurs
in specialized structures at the ends of cardiomyocytes called
intercalated discs. The lateral borders of the myocytes usually
show variable amounts of gap junctions depending on age or
disease. Melatonin receptor activation has been shown to
protect against low potassium-induced ventricular fibrilla-
tion by shortening the AP, preserving ventricular electrical
activation, and preventing acute changes in Cx43 distribu-
tion [221]. Melatonin has been shown to prevent myocardial
abnormalities arising due to structural changes andmodifica-
tion of connexin localization and to improve cardiac conduc-
tion [198]. Additionally, melatonin has been shown to
protect against arrhythmias by increasing the myocardial
Cx43 by PKC in hypertensive rats [198].
Although most studies on melatonin action in the heart
focus on its antiarrhythmic protection in relation to its antiox-
idant properties [222–228], new antiarrhythmic effects have
been associated with oxidative stress-independent action on
other cardiac properties, such as ventricular activation [197],
thus opening the route for the study of additional attributes
of this promising therapeutic agent. Some studies have docu-
mented an antiarrhythmic effect of melatonin in isolated
hearts of female rats when administered continuously from
the stage prior to the onset of myocardial ischemia [196]. Also,
melatonin reduces arrhythmias when administered during
reperfusion. Specifically, melatonin has shown to have a
protective action when administered to isolated hearts of
hypertensive rats [14]. These animals show greater activity of
the enzyme NADPH oxidase, which is one of the main sys-
tems for generating free radicals, and, therefore, higher levels
of oxidative stress, which is involved in the generation of early
and delayed afterdepolarizations [229]. The acute administra-
tion of melatonin during low potassium perfusion reduced the
incidence of ventricular fibrillation and improved the recovery
of sinus rhythm. Protection was mediated by activation of
melatonin receptors and by prevention of dephosphorylation
and lateralization of Cx43 [221].
4.5. Pharmacological Consideration Regarding Melatonin
Administration.Melatonin is a safe molecule without serious
adverse effects in a broad range of concentrations either
when administered orally or intravenously [230–234]. For
antiarrhythmic purposes, two main approaches should be
taken into account: first, an acute administration in the con-
text of high proarrhythmic conditions or to treat an ongoing
arrhythmia, and second, a chronic preventive one for situa-
tions with increased risk of arrhythmias.
The intravenous bioavailability of melatonin is 100%
after a bolus administration and decays biexponentially with
half-lives within 2 minutes and 20 minutes [235]. Oral
administration reaches a peak concentration around 45
minutes with bioavailability ranging from 3 to 33%, accord-
ing to different reports. Due to its hydro- and lipophilic prop-
erties, melatonin can easily reach the membranes and the
inner organelles. Therefore, the potential as an antiarrhyth-
mic to act in the acute scenario is clearly available. However,
the evidence is still mainly preclinical [14, 198, 221, 229, 236].
In the context of ischemia/reperfusion, simultaneous intrave-
nous and intracoronary administration has been proven to be
electrophysiologically safe. Formulations of melatonin in
polyethylene glycol or saline solution at doses from 14 to
50mg did not affect the electrophysiological response of the
myocardium under ischemia/reperfusion conditions [237,
238]. Unfortunately, both clinical studies failed to prove the
cardioprotective effect of melatonin against infarct size. The
studies were not designed to evaluate severe reperfusion
arrhythmias like sustained ventricular tachycardia and
ventricular fibrillation.
Oral doses in an acute cardiac scenario ranged from 3mg
to 25mg and displayed a safe electrophysiological profile
despite mixed cardioprotection results. A conservative
approach of 3mg of melatonin, started on the night following
the primary percutaneous coronary intervention and contin-
ued daily during the hospitalization, had mixed results on
enzymatic myocardial infarct size [239]. Pretreatment with
melatonin during five days before coronary artery bypass
grafting surgery reduced myocardial injury, heart rate, oxida-
tive stress, and inflammatory markers when compared to pla-
cebo [240]. On the other hand, 25mg melatonin administered
for twelve weeks following acute coronary syndrome may
aggravate endothelial dysfunction [241]. Interestingly, the
combination of 50mg intravenously and 10mg orally display
cardioprotection in patients undergoing abdominal aortic
aneurysm repair, with a risk reduction of 25% of cardiac
morbidity, including postoperative atrial fibrillation [242].
Several safety studies showed the lack of severe side effects
of melatonin during chronic and sustained administration
[243–245]. Regarding arrhythmias, one report of two patients
suffering frequent premature ventricular contractions claimed
that arrhythmic events resolved after stopping melatonin 1mg
as their sleeping pills [246]. On the other hand, several studies
validated the melatonin safety profile during long periods of
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supervised side effect evaluation. No prospective clinical
research has been conducted to evaluate melatonin as an
antiarrhythmic. Several preclinical studies postulate melatonin
as a preventive agent against ventricular arrhythmias [13, 15,
197, 198, 247, 248]. The proarrhythmic vs. antiarrhythmic
effect of melatonin deserves further translational and clinical
studies.
5. Preventive Perspectives: The Fountain of
Youth for the Heart
We gave an overview of the positive effect of melatonin and
focused our attention on its role as a future possible treatment
aimed at reducing the risk of cardiac arrhythmias in aged
hearts. As described in this review, the structural and func-
tional remodeling that accompanies aging increases suscepti-
bility to atrial and ventricular arrhythmias in humans and in
animal models. The increase in oxidative stress with aging
plays a major role in this age-associated remodeling. When
antioxidant defenses, which decline with aging, are not able
to counteract the elevated levels of oxidative stress, arrhyth-
mias can manifest with higher probability. On this basis, we
bring here a summary of the variety of positive effects of
melatonin. This molecule could be one of the new keys to find
the fountain of youth against adverse age-related remodeling
of the heart (Figure 3). Several drugs have been described as
novel, potential antiarrhythmic agents mainly for the manage-
ment of AF in the elderly. However, more research is expected
to lead to new strategies for prevention or treatment of
arrhythmias in the elderly, including ventricular arrhythmias.
Previous studies have described the protective role of mel-
atonin against autophagy and apoptosis in cardiomyocytes via
regulation of mitochondrial uncoupling protein 2 (UCP2),
producing a mechanism of protection against lipopolysaccha-
rides (LPS) [249]. However, the protective mechanism of
melatonin goes far beyond this action, involving different roles
in the nervous system [250–252], myocardium remodeling
[17] and antioxidant properties [162], all these factors
generally involved in its receptor-mediated actions linked to
antiarrhythmic properties. This substantiates that melatonin
becomes a molecule worthy to be further explored for use in
clinical applications. Elevated heterogeneities in cardiac con-
duction and AP repolarization, which may occur in relation
to aging and other cardiac diseases, can be reduced by melato-
nin via its action in the modulation of myocardial Cx43 [198]
and ion channels, improvement of cardiomyocyte physiology,
and generation and conduction of APs, ultimately protecting
against arrhythmogenesis [18, 56].
Moreover, melatonin synchronizes central but also
peripheral oscillators like the heart, allowing temporal orga-
nization of biological functions through circadian rhythms
and improving adaptation of the individual to the internal
and external environment, thus working as a good antiaging
agent [182]. Furthermore, numerous studies have confirmed
the antiarrhythmic protection of melatonin and have related
it to its remarkable antioxidant properties under a time- and
dose-dependent response. As an example of these facts, stud-
ies in hypertensive rat hearts, which have a higher activity of
the enzyme NADPH oxidase implicated in oxidative stress
and present high arrhythmic risk, have shown that treatment
with melatonin has positive effects, avoiding arrhythmias,
either sustained ventricular tachycardia or ventricular fibril-
lation [18, 198, 229].
Based on the number and diversity of major melatonin
benefits, there is also a perspective for measuring melatonin
not only as a possible treatment to defeat cardiovascular
problems but also as a biomarker to detect, control, and
follow-up certain disorders. Melatonin could become essential
for clinical preventive and therapeutic applications in new-
borns, children, and adults based on its physiological regula-
tory effects [182]. However, it is crucial to take into account
that its role can be time- and dose-dependent so as to avoid
possible adverse effects [246, 253]. In addition, considering
that the ability of the pineal gland to produce melatonin is
compromised during aging, with a gradual decrease in blood
melatonin levels at night, the potential use of melatonin as an
early biomarker indicative of adverse age-induced remodeling
associated with arrhythmic risk is anticipated [183].
Among the list of potential antiarrhythmic molecules and
based on the antioxidant action and pleiotropic effects of
melatonin in organisms, it has been described as one of the
potential antioxidant targets in cardiac tissue [226]. Melato-
nin concentrations and its associated effects can highly vary
from one individual to another as well as in relation to aging
or chronic diseases. Among many effects, melatonin has
shown an important role as an inhibitor of lipid peroxida-
tion. Due to this effect, melatonin plays a crucial role in












Figure 3: The balance between oxidative stress and antioxidant
defenses influence the evolution of cardiac age-induced remodeling
and the level of proarrhythmic risk. Increases in oxidative stress
anticipate the occurrence of arrhythmic events, whereas antioxidants
delay or even abrogate arrhythmias.
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of protecting them. Besides, melatonin can act as a direct free
radical scavenger and also an indirect antioxidant. Addition-
ally, its metabolites are efficient in scavenging ROS and reac-
tive nitrogen species. Melatonin also plays an effective action
related to mitochondrial homeostasis [165]. Based on cell
energy impairment, apoptosis, and overproduction of ROS
as pathogenic mechanisms in aging melatonin could play a
crucial role in counteracting deleterious aging [135, 137],
effects in the cardiovascular system, particularly considering
its antioxidant action. In conclusion, melatonin is a molecule
representing a new target to be further tested in clinical trials
expanding its application beyond sleep problems or a few
already explored disorders. Future studies on dose-response
relationships will be crucial to extend the use of melatonin
in clinical practice, for both treatment and prevention, par-
ticularly in the context of cardiac arrhythmias in aged hearts.
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